


Small Molecule Kinase Inhibitors

SYNkinase is a primary producer of over 200 research-use-only small molecule **Kinase Inhibitors**, for life science and drug discovery researchers.

Key Features

- Includes Many Unique Small Molecules
- Versatile Research-relevant Targets
- High Quality & Highly Pure Compounds
- In-house Manufactured – Available in BULK!
- All Compounds Available in Catalog Sizes from 1–100 mg



New from the Bench

Potent MLK-3 & LRRK2 Inhibitor


URMC-099

SYN-1211

Formula: C₂₇H₂₇N₅

MW: 421.5

CAS: 1229582-33-5



Inhibition of MLK-3 is a strategy for the treatment of Parkinson's disease and HIV-1 associated neurocognitive disorders (HAND). URMC-099 is an orally bioavailable MLK-3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or human ERG channels. It inhibits multiple kinase pathways including MLK-3 (14nM) and LRRK2 (11nM).

 Unique to SYNkinase

Visit www.adipogen.com for a complete Overview on all Kinase Inhibitors!

Unique SYNkinase Inhibitors


PRODUCT	PAGE
JAK/STAT Pathway Inhibitors	2
Growth Factor Inhibitors	2
PI3K/AKT/mTOR Pathway Inhibitors	3
MAPK Pathway Inhibitors	3
Cell Cycle Inhibitors	4
Selected Other Inhibitors	4

COLLABORATING WITH

AdipoGen[®] 

EGFR-JAK/STAT Signaling Pathway

JAK tyrosine kinases and STAT transcription factors constitute a signaling pathway, which is activated by cytokines, such as EGFR (see pathway) and consequently activates e.g. MAPK and mTOR pathways. By activating gene transcription it regulates essential biological responses, involved in the regulation of cell development, differentiation, immune cell proliferation, apoptosis and inflammation. Improper function of this pathway may contribute to hematopoietic malignancies and cancer.



Potent Selective TYK2 Inhibitor


GDC-046

SYN-1198

Formula: C₁₆H₁₃Cl₂N₃O₂

MW: 350.2






CAS: 1258292-64-6









Potent selective TYK2 inhibitor (K_i=4.8nm) versus JAK1 (K_i=84nm) and JAK2 (K_i=28nm). Lead compound with good kinase selectivity, physico-chemical properties and pharmacokinetic profile.




 *Unique to SYNkinase*






JAK/STAT Pathway Inhibitors

PRODUCT NAME	TARGETS	PID
 GLPG0634	JAK1, JAK2	SYN-1158
 Baricitinib . phosphate	JAK1, JAK2	SYN-1117
NVP-BSK805 . 2HCl	JAK2	SYN-1136
 CEP-33779	JAK2	SYN-1156
XL019	JAK2	SYN-1191
 TG-46	JAK2, FLT3, RET, JAK3	SYN-1106
 TG-89	JAK2, FLT3, RET, JAK3	SYN-1107
Merck-5	JAK1, JAK2, JAK3, TYK2	SYN-1054

PRODUCT NAME	TARGETS	PID
 Bayer-18	TYK2	SYN-1130
 RO495	TYK2	SYN-1128
 PRT-060318	SYK	SYN-1204
TAK-632	pan-RAF	SYN-1203
 GSK25	RSK1, p70S6K	SYN-1124
 PD-173955-Analog1	c-Src kinase (CSK)	SYN-1062
 PF-4618433	PYK2	SYN-1163
PF-431396	FAK, PYK2	SYN-1063
CX-6258	Pim-1, Pim-2, Pim-3	SYN-1182

Growth Factor Inhibitors

PRODUCT NAME	TARGETS	PID
 AV-412	EGFR, ErbB2 (HER2) kinases	SYN-1012
 CP-724714	ErbB2 (HER2) kinases	SYN-1033
 AG13958	VEGF	SYN-1004
Tivozanib	VEGFR-1, 2 & 3	SYN-1013
Motesanib	VEGFR-1, 2 & 3, PDGFR, c-Kit	SYN-1055
Regorafenib	VEGFR-1, 2 & 3, PDGFR, c-Kit, RET, Raf-1	SYN-1169

PRODUCT NAME	TARGETS	PID
Pazopanib	VEGFR, PDGFR, c-Kit	SYN-1058
SU-5402	VEGFR-2 (KDR), FGFR1	SYN-1084
 JNJ-38158471	VEGFR-2 (KDR)	SYN-1133
 SAR-131675	VEGFR-3	SYN-1165
 Takeda-6d	B-Raf, VEGFR-2 (KDR)	SYN-1168
 AMG-25	c-Kit	SYN-1125
 AMG-Tie2-1	Tie-2	SYN-1008



PI3K/AKT/mTOR Signaling Pathway

The mTOR pathway is involved in many processes, including tumor formation, angiogenesis, autophagy, apoptosis, insulin resistance, adipogenesis and T-lymphocyte activation. Aberrant activation of the PI3K pathway has been widely implicated in many cancers and increased activity of this pathway is often associated with resistance to cancer therapies.

Potent PI3K/mTOR Dual Kinase Inhibitor


PF-04979064

SYN-1194


Formula: C₂₄H₂₆N₆O₃

MW: 446.5

CAS: 1258292-64-6



Potent and selective PI3K/mTOR dual kinase inhibitor. Shows potent K_i values against PI3K α (K_i=0.13nM human, 0.299nM mouse), PI3K γ (K_i=0.111nM) and PI3K δ (K_i=0.122nM) in direct kinase assays. K_i value for mTOR is 10X higher at 1.42nM.



PI3K/AKT/mTOR Pathway Inhibitors

Unique to SYNkinase

PRODUCT NAME	TARGETS	PID
PIK-75	PI3K (p110 α isoform)	SYN-1067
TASP0415914	PI3K (p110 γ isoform)	SYN-1208
PIK-90	PI3K (p110 α / δ / γ isoform)	SYN-1068
GDC-0032	PI3K (p110 α / δ / γ isoform)	SYN-1202
GNE-490	pan-PI3K	SYN-1114
GNE-493	pan-PI3K/mTOR	SYN-1115
NIBR-17	Class I PI3K	SYN-1145
GNE-477	Dual PI3K/mTOR	SYN-1148
BGT226	PI3K	SYN-1178A
Akt-I-1	Akt1	SYN-1005
Akt-I-2 . HCl	Akt1, Akt2	SYN-1006

PRODUCT NAME	TARGETS	PID
Merck-22-6	Akt1, Akt2	SYN-1118
A-674563 . HCl	Akt1, PKA, CDK2	SYN-1110
AZD-26	Akt	SYN-1160
S6K-18	S6K1	SYN-1132
BLZ-945	CSF-1R	SYN-1197
JNJ-28312141	CSF-1R, FLT3	SYN-1154
KW-2449 . HCl	FLT3	SYN-1205
AST-487	FLT3	SYN-1210
AMG-51	c-Met	SYN-1111
SGX-523	c-Met	SYN-1155
AMG-1	c-Met, RON	SYN-1143

Small Molecule Kinase Inhibitors

MAPK Pathway Inhibitors

PRODUCT NAME	TARGETS	PID
CC-401 . HCl	JNK (all 3 forms)	SYN-1028
Bentamapimod	JNK	SYN-1147
SD-06	p38 α MAPK	SYN-1078
SD-169	p38 α MAPK	SYN-1079
RWJ-67657	p38 α / β MAPK	SYN-1072

PRODUCT NAME	TARGETS	PID
SB242235	p38 MAPK	SYN-1076
R1487 . HCl	p38 MAPK	SYN-1101
S-99	ASK1	SYN-1119
AMG-47a	Lck, KDR, SRC, p38 MAPK	SYN-1007
CH4987655	MEK	SYN-1188

Cell Cycle Regulation

The cell cycle is regulated by the interplay of many molecules. Key among these are cyclins which combine with cyclin dependent kinases (CDKs) to form activated kinases that phosphorylate targets leading to cell cycle regulation. A breakdown in the regulation of this cycle leads to uncontrolled cell division or propagation of damaged DNA which can contribute to genomic instability and tumorigenesis. Defects in many of the molecules, that regulate the cell cycle, have been implicated in cancer.

ATP-competitive Potent CHK1 Inhibitor


SAR-020106

SYN-1189


Formula: C₁₉H₁₉ClN₆O

MW: 382.9





CAS: 1184843-57-9





ATP-competitive, potent and selective CHK1 inhibitor with an IC₅₀ of 13.3nM on the isolated human enzyme. Inhibits cytotoxic drug-induced autophosphorylation of CHK1 at S296 in a dose-dependent fashion both *in vitro* and *in vivo*.






Cell Cycle Inhibitors


PRODUCT NAME	TARGETS	PID
CX-4945	CK2	SYN-1109
 AT7519 . HCl	CDKs	SYN-1010
 PHA-690509	CDK2	SYN-1097
 BMS-387032 . HCl	CDK2, CDK7, CDK9	SYN-1080
Alvocidib	CDK1, CDK2, CDK4, CDK6	SYN-1040
 BS-194	CDK1, CDK2, CDK5, CDK7,	SYN-1151

PRODUCT NAME	TARGETS	PID
Purvalanol B	Cdc2/cyclin B, CDK2/cyclin A,	SYN-1070
SNS-314	pan-Aurora Kinase	SYN-1081
 PD-173955	Dual Src/Bcr-Abl kinase	SYN-1061
 BMS-3	LIMK1, LIMK2	SYN-1023
BMS-5	LIMK1, LIMK2	SYN-1024

Selected Other Inhibitors

PRODUCT NAME	TARGETS	PID
SR3677	ROCK-I, ROCK-II	SYN-1083
 VTX-27	PKCθ	SYN-1206
 SP2509	LSD1	SYN-1212

PRODUCT NAME	TARGETS	PID
GCI1746	BTK	SYN-1164
 RN486 . TFA	BTK	SYN-1184
GSK2606414	PERK	SYN-1201

 Unique to SYNkinase

 collaborating with

AdipoGen[®]

EUROPE/REST OF WORLD
Adipogen International
TEL +41-61-926-60-40
FAX +41-61-926-60-49
info@adipogen.com

NORTH & SOUTH AMERICA
Adipogen Corp.
TEL +1-858-457-8383
FAX +1-858-457-8484
info-us@adipogen.com

For local distributors please visit our website.

www.adipogen.com